 2006 |
|
 November
13 |
Avontec (Germany) Starts Phase IIa Clinical Trials of AVT-01
- Obtaining Approval for Initiation of Clinical Trials in the Field of Asthma in Europe - |
| October 31 |
AnGes MG Launches Phase II Clinical Trials of NF-κB Decoy Oligo in the Treatment of Atopic Dermatitis in Japan |
| October 18 |
Efficacy of Drug Delivery System (DDS) Nanoparticles Supported Nucleic Acid
Medicine for Atopic Dermatitis, Developed by Hosokawa Powder Technology
Research Institute and AnGes MG, Inc. Confirmed in Animal Experiments |
| September 7 |
AnGes MG Submitted the Notification of the Clinical Trial Plan for NF-κB Decoy Oligo
- Phase II Clinical Trials of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis Commences - |
| June
5 |
AnGes MG, Inc. Announce their Policy for Future Development of HGF Gene Therapy |
| June
5 |
AnGes MG, Inc. Releases the Results of the US Phase II
Clinical Trial with HGF Gene Plasmid for PAD (Peripheral Arterial Disease) |
| June
1 |
Completion of Reexamination of the Basic US Patent on
NFκB Decoy Oligonucleotide
-Decision to Maintain Patent- |
| May
30 |
AnGes MG, Inc. and Vical Inc. Sign Collaborative R&D Agreement for Allovectin-7® as well as Equity Investment Agreement |
| May
26 |
Results of Phase I Clinical Trials of NFκB Decoy Oligo
in the Treatment of Atopic Dermatitis |
| May
24 |
A Japanese Medical-Use Patent is Granted for NFκB Decoy Oligonucleotide
-Covering Treatment for Atopic Dermatitis- |
| May
8 |
Results of the US Phase I Clinical Trials with HGF Gene Plasmid for Ischemic Heart Disease (IHD) |
| April
3 |
AnGes MG, Inc. Announces Newly Establishing a Position of CIPO(Chief Intellectual Property Officer) |
| February
22 |
AnGes MG, Inc. Announced Preliminary Results of the US Phase II Clinical
Trial with HGF Gene Therapy for PAD (Peripheral Arterial Disease) |
| February
3 |
Termination of Joint Development with Seikagaku Corporation |
| January 31 |
Medical-Use Patent for HGF Gene Granted in U.S.
- Covering Cardiomyopathy - |
